With further research, even monoclonal antibody medications such as ustekinumab (Stelara®), which has been proven to be a good adjuvant in the management of Crohn’s disease by inhibiting the IL-23/IL-17 axis, could be a potential impact to limit the progression of the immune and inflammatory response to PD [34]. This evidence concerns the gene IL17A and Crohn disease.